Navigation Links
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Date:8/28/2007

ss than $35 million, compared to original guidance estimates of approximately $40 million. Sunesis expects its 2008 cash used in operating activities to be at or below its 2007 level.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the safety and potential efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the anticipated timing of the commencement and completion of clinical trials and the announcement of clinical results, whether any future trial will constitute a registration trial sufficient to support an application for regulatory approval, potential corporate partnerships or collaborations, plans to strategically invest in drug discovery efforts, ability to advance high-quality lead candidates into preclinical and clinical development, the estimated reduction in Sunesis' operating expenses, the estimated restructuring charges to be incurred in the third quarter, and Sunesis' ongoing cash requirements . Words such as "anticipates," "plans," "will," "optimistic," "is expected" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
(Date:8/20/2014)... 2014 The 6th Annual Arrowhead ... on October 29-30 in San Francisco, CA. This year’s ... government researchers and clinicians focused on addressing and solving ... In the twelve years since the sequencing of the ... introduced with pharmacogenetic information in the label and molecular ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... NJ (PRWEB) August 20, 2014 WriteResult®, ... announced today that it has expanded its myPROpad™ ePRO ... the EQ-5D-5L, one of the most widely used ... measuring general health status. The EQ-5D is used during ... generate a measure that can be used to demonstrate ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2
... AUCKLAND, New Zealand, Jan. 6 MicroDose Technologies, ... have entered into a collaboration to investigate the ... generation electronic dry powder inhaler (DPI). Under ... the development of prototypes based upon MicroDose,s inhaler ...
... leader in providing automated, molecular testing solutions, announced today ... to present at the JPMorgan Healthcare Conference, which will ... Francis Hotel in San Francisco, CA. At this conference, ... of the Company at 11:00am on Tuesday, January 13, ...
... in drug-eluting stent technologyNATICK, Mass., Jan. 6 ... today announced that it has acquired Labcoat Limited, ... located in Galway, Ireland. Terms of the ... technology for coating drug-eluting stents that uses precisely ...
Cached Biology Technology:MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 2MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDose's Electronic Dry Powder Inhaler 3Boston Scientific Acquires Labcoat Limited 2Boston Scientific Acquires Labcoat Limited 3Boston Scientific Acquires Labcoat Limited 4
(Date:8/21/2014)... A study recently published in the journal ... shows a new role for the protein adenomatous polyposis ... cause of cancer-related deaths in the U.S. , Lead ... Molecular Biosciences and co-leader of the Cancer Biology program ... part of her career trying to understand the various ...
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... Network(R) Video Reports , , ... , April 27 The U.S. Supreme Court has denied the ... Richard I. Fine who has never been charged with ... in L.A. County Central Men,s jail for over a year.  Fine attempted to ...
... 2010 Dominio Amigo S.A.S , a .CO,accredited domain name registrar, ... , , ... , CEO, Dominio Amigo S.A.S , commented, "Domainmonster was a,simple choice for ... gTLD launches, securing the very best Internet real estate,for their customers." "With a ...
... NEW BERN, N.C. , April 27 A hurricane ... your business, information, because you really haven,t thought about it until now. ... Atlantic region, now,s the time to update your document storage plans so ... , , ...
Cached Biology News:U.S. Supreme Court Allows 'Coercive Confinement' to Continue in Attorney's Civil Contempt Case 2U.S. Supreme Court Allows 'Coercive Confinement' to Continue in Attorney's Civil Contempt Case 3Dominio Amigo Announce Domainmonster as .CO Technical Partner 2Dominio Amigo Announce Domainmonster as .CO Technical Partner 3Hurricane-Proof Your Information 2
...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
...
Biology Products: